<DOC>
	<DOCNO>NCT01053507</DOCNO>
	<brief_summary>This study evaluate effectiveness Treximet take post traumatic headache measure change number headache day change subject 's ability think follow treatment study medication . Eligible subject complete 3 visit . Following Visit 1 , subject treat usual medication document headache symptom therapy Headache Diary . After 30 day , subject return Visit 2 randomize ( like flip coin ) receive Treximet match placebo treat time day . Treximet provide treat headache occur . Subjects complete daily Diary . After 30 day , subject exit study Visit 3 .</brief_summary>
	<brief_title>Treximet Prevention Post Traumatic Headache Associated With Cognitive Dysfunction</brief_title>
	<detailed_description>Subjects enrol 3 investigative site . At Visit 1 , medical , headache , medication history collect physical neurological exam vital sign perform . An ECG complete one complete previous 6 month . Subjects administered series psychological test help study doctor decide whether subject eligible . The Headache Impact Test-6 Migraine Specific Quality Life Questionnaire complete visit . During 30-day Baseline Period , subject treat usual medication complete daily Diary documenting headache symptom treatment . At Visits 2 3 subject complete Mental Efficiency Workload Test Migraine Early Warning Tool . Following randomization Visit 2 , subject treat daily 30 day Treximet match placebo . Subjects provide Treximet rescue persist recur headache . During Treatment Period , subject complete daily Diary reporting headache symptom response treatment . After 30-day Treatment Period , subject exit study Visit 3 .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Post-Traumatic Headache</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject male female age 1865 . A female eligible enter participate study : a.nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; , b . childbearing potential , negative pregnancy test ( urine serum ) Visit 2 , agree one following : Complete abstinence intercourse 2 week prior administration investigational product , throughout study , time interval ( 5 day ) completion premature discontinuation study account elimination investigational drug ; subject utilize method must agree use alternate method contraception become sexually active query whether abstinent present clinic final visit , Female sterilization ; , Sterilization male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combine progestogen ) ; , Any intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Spermicide plus mechanical barrier ( e.g. , spermicide plus male condom female diaphragm ) ; , Any barrier method ( use combination acceptable method ) ; , Any method publish data show high expected failure rate method le 1 % per year . formally diagnosed International Classification Headache Disorders ( ICHD ) 5.2.2 chronic post traumatic headache &gt; 15 headache day per month past 3 month headache , leave untreated , would least 1 symptom migraine ( nausea , vomit , photophobia , phonophobia ) respond triptan ergotaminecontaining medication least 50 % headache medically stable determine Investigator take headache preventive medication , stabilize dosage least 30 day prior screen . take concomitant medication , stabilize dosage discretion investigator chronic headache history traumatic brain injury ( TBI ) able understand communicate intelligibly study observer able take oral medication , adhere medication regimen perform study procedure able read comprehend write instruction willing complete procedure assessment require protocol able demonstrate willingness participate sign understand informed consent full explanation study selfreported cognitive inefficiency `` brainfog '' headache Subject history serotonin syndrome medical condition , opinion investigator , could alter response study medication confound result study female childbearing potential use adequate contraceptive measure history retinal , basilar hemiplegic migraine , cluster headache , secondary headache ( due infection , alteration homeostasis , ear nose throat ( ENT ) psychiatric disorder , cranial cervical disorder neuralgias ) investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease ( base history presence risk factor include limited , hypertension , hypercholesterolemia , smoker , obesity , diabetes , family history coronary artery disease ) blood pressure â‰¥140/90 millimeter mercury ( mmHg ) 2 3 BP measurement screen take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker history significant congenital heart disease , cardiac arrhythmia require medication , history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study evidence history ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome , signs/symptoms consistent evidence history central nervous system pathology include stroke and/or transient ischemic attack ( TIAs ) , epilepsy structural brain lesion lower convulsive threshold ; treat antiepileptic drug seizure control within 5 year prior screen history impaired hepatic renal function , investigator 's opinion , contraindicate participation study hypersensitivity , intolerance , contraindication use triptan , nonsteroidal antiinflammatory drug ( NSAID ) aspirin ( include sumatriptan naproxen preparation ) nasal polyps asthma currently take , take previous three month , migraine prophylactic medication contain methysergide ; take migraine menstrual migraine prophylactic medication stabilize ( i.e . start change dose within 30 day prior screen ) recent history regular use opioids barbiturates treatment migraine headache and/or nonmigraine pain medication overuse opinion investigator exacerbate contribute current headache pattern subject . take , plan take , monoamine oxidase inhibitor ( MAOI ) , include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) , anytime within 2 week prior screen 2 week post final study treatment . history bleed disorder currently take anticoagulant antiplatelet agent . evidence history gastrointestinal surgery GI ulceration perforation past six month , gastrointestinal bleeding past year ; evidence history inflammatory bowel disease pregnant , actively try become pregnant , breast feeding evidence alcohol substance abuse within last year concurrent medical psychiatric condition , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial . participated investigational drug trial within previous four week plan participate another study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Headache</keyword>
	<keyword>Post-traumatic headache</keyword>
	<keyword>Brain injury</keyword>
	<keyword>Cognitive impairment</keyword>
</DOC>